Integrated Multi-omics for Rapid Rare Disease Diagnosis on a National Scale

Critically ill infants and children with rare diseases need equitable access to rapid and accurate diagnosis to direct clinical management. Over 2 years, the Acute Care Genomics program provided whole-genome sequencing to 290 families whose critically ill infants and children were admitted to hospitals throughout Australia with suspected genetic conditions. The average time to result was 2.9 d and diagnostic yield was 47%. We performed additional bioinformatic analyses and transcriptome sequencing in all patients who remained undiagnosed. Long-read sequencing and functional assays, ranging from clinically accredited enzyme analysis to bespoke quantitative proteomics, were deployed in selected cases. This resulted in an additional 19 diagnoses and an overall diagnostic yield of 54%. Diagnostic variants ranged from structural chromosomal abnormalities through to an intronic retrotransposon, disrupting splicing. Critical care management changed in 120 diagnosed patients (77%). This included major impacts, such as informing precision treatments, surgical and transplant decisions and palliation, in 94 patients (60%). Our results provide preliminary evidence of the clinical utility of integrating multi-omic approaches into mainstream diagnostic practice to fully realize the potential of rare disease genomic testing in a timely manner.

Citing Articles

Unraveling MECP2 structural variants in previously elusive Rett syndrome cases through IGV interpretation.

Poleg T, Hadar N, Heimer G, Dolgin V, Aminov I, Safran A NPJ Genom Med. 2025; 10(1):23.

PMID: 40082422 PMC: 11906642. DOI: 10.1038/s41525-025-00481-9.

International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease.

Howell K, White S, McTague A, DGama A, Costain G, Poduri A NPJ Genom Med. 2025; 10(1):13.

PMID: 40016282 PMC: 11868529. DOI: 10.1038/s41525-025-00474-8.

Quantifying hope: an EU perspective of rare disease therapeutic space and market dynamics.

Cacoub E, Lefebvre N, Milunov D, Sarkar M, Saha S Front Public Health. 2025; 13:1520467.

PMID: 39963479 PMC: 11830808. DOI: 10.3389/fpubh.2025.1520467.

Multi-omics profiling in spinal muscular atrophy (SMA): investigating lipid and metabolic alterations through longitudinal CSF analysis of Nusinersen-treated patients.

Zandl-Lang M, Zullig T, Holzer M, Eichmann T, Darnhofer B, Schwerin-Nagel A J Neurol. 2025; 272(3):183.

PMID: 39904776 PMC: 11794407. DOI: 10.1007/s00415-025-12909-4.

Genomic exploration of pediatric neurological disorders: a case series.

Tayade N, Manoj G, Kewat A, A A, Devulapalli R, Kumar S J Med Case Rep. 2025; 19(1):43.

PMID: 39891267 PMC: 11786458. DOI: 10.1186/s13256-025-05052-1.

References

Stark Z, Dolman L, Manolio T, Ozenberger B, Hill S, Caulfied M . Integrating Genomics into Healthcare: A Global Responsibility. Am J Hum Genet. 2019; 104(1):13-20. PMC: 6323624. DOI: 10.1016/j.ajhg.2018.11.014. View

Clark M, Stark Z, Farnaes L, Tan T, White S, Dimmock D . Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018; 3:16. PMC: 6037748. DOI: 10.1038/s41525-018-0053-8. View

Lunke S, Eggers S, Wilson M, Patel C, Barnett C, Pinner J . Feasibility of Ultra-Rapid Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic Conditions in the Australian Public Health Care System. JAMA. 2020; 323(24):2503-2511. PMC: 7312414. DOI: 10.1001/jama.2020.7671. View

Dimmock D, Caylor S, Waldman B, Benson W, Ashburner C, Carmichael J . Project Baby Bear: Rapid precision care incorporating rWGS in 5 California children's hospitals demonstrates improved clinical outcomes and reduced costs of care. Am J Hum Genet. 2021; 108(7):1231-1238. PMC: 8322922. DOI: 10.1016/j.ajhg.2021.05.008. View

Stark Z, Ellard S . Rapid genomic testing for critically ill children: time to become standard of care?. Eur J Hum Genet. 2021; 30(2):142-149. PMC: 8821543. DOI: 10.1038/s41431-021-00990-y. View

Gorzynski J, Goenka S, Shafin K, Jensen T, Fisk D, Grove M . Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting. N Engl J Med. 2022; 386(7):700-702. DOI: 10.1056/NEJMc2112090. View

Kingsmore S . 2022: a pivotal year for diagnosis and treatment of rare genetic diseases. Cold Spring Harb Mol Case Stud. 2022; 8(2). PMC: 8958907. DOI: 10.1101/mcs.a006204. View

Smedley D, Smith K, Martin A, Thomas E, McDonagh E, Cipriani V . 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. N Engl J Med. 2021; 385(20):1868-1880. PMC: 7613219. DOI: 10.1056/NEJMoa2035790. View

Stranneheim H, Lagerstedt-Robinson K, Magnusson M, Kvarnung M, Nilsson D, Lesko N . Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Med. 2021; 13(1):40. PMC: 7968334. DOI: 10.1186/s13073-021-00855-5. View

10.

Kingsmore S, Cakici J, Clark M, Gaughran M, Feddock M, Batalov S . A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in Ill Infants. Am J Hum Genet. 2019; 105(4):719-733. PMC: 6817534. DOI: 10.1016/j.ajhg.2019.08.009. View

11.

Brockman D, Austin-Tse C, Pelletier R, Harley C, Patterson C, Head H . Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. Genet Med. 2021; 23(9):1689-1696. PMC: 8488861. DOI: 10.1038/s41436-021-01193-y. View

12.

Seaby E, Rehm H, ODonnell-Luria A . Strategies to Uplift Novel Mendelian Gene Discovery for Improved Clinical Outcomes. Front Genet. 2021; 12:674295. PMC: 8248347. DOI: 10.3389/fgene.2021.674295. View

13.

Morales J, Welter D, Bowler E, Cerezo M, Harris L, McMahon A . A standardized framework for representation of ancestry data in genomics studies, with application to the NHGRI-EBI GWAS Catalog. Genome Biol. 2018; 19(1):21. PMC: 5815218. DOI: 10.1186/s13059-018-1396-2. View

14.

Robinson P, Kohler S, Bauer S, Seelow D, Horn D, Mundlos S . The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet. 2008; 83(5):610-5. PMC: 2668030. DOI: 10.1016/j.ajhg.2008.09.017. View

15.

Alsina Casanova M, Monteagudo-Sanchez A, Rodiguez Guerineau L, Court F, Gazquez Serrano I, Martorell L . Maternal mutations of FOXF1 cause alveolar capillary dysplasia despite not being imprinted. Hum Mutat. 2017; 38(6):615-620. DOI: 10.1002/humu.23213. View

16.

Neilson D, Adams M, Orr C, Schelling D, Eiben R, Kerr D . Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009; 84(1):44-51. PMC: 2668029. DOI: 10.1016/j.ajhg.2008.12.009. View

17.

Halman A, Dolzhenko E, Oshlack A . STRipy: A graphical application for enhanced genotyping of pathogenic short tandem repeats in sequencing data. Hum Mutat. 2022; 43(7):859-868. PMC: 9541159. DOI: 10.1002/humu.24382. View

18.

Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F . Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet. 2010; 87(2):250-7. PMC: 2917705. DOI: 10.1016/j.ajhg.2010.06.015. View

19.

Niemeyer C, Kang M, Shin D, Furlan I, Erlacher M, Bunin N . Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010; 42(9):794-800. PMC: 4297285. DOI: 10.1038/ng.641. View

20.

Smallwood K, Watt K, Ide S, Baltrunaite K, Brunswick C, Inskeep K . POLR1A variants underlie phenotypic heterogeneity in craniofacial, neural, and cardiac anomalies. Am J Hum Genet. 2023; 110(5):809-825. PMC: 10183370. DOI: 10.1016/j.ajhg.2023.03.014. View